A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Latest Information Update: 12 May 2026
At a glance
- Drugs SGT 003 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Acronyms INSPIRE DUCHENNE
- Sponsors Solid Biosciences
Most Recent Events
- 30 Apr 2026 According to Solid Biosciences media release, the data from the trial will be presented at the upcoming 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 2026.
- 20 Mar 2026 According to Solid Biosciences media release, 41 participants dosed as of March 18, 2026.
- 11 Mar 2026 According to Solid Biosciences media release, The interim update was delivered in an oral presentation at the 2026 MDA Annual Meeting on March 11, 2026,